Alternative and repurposed cancer interventions span a broad spectrum ranging from landmark clinical trial-backed drugs to experimental dietary and metabolic strategies. The literature structures these interventions into a four-tiered evidence hierarchy according to the quality and volume of human clinical data.
1. Evidence Tier Framework
Tier 1: Strong Clinical Evidence
Supported by meta-analyses of randomized controlled trials (RCTs) or landmark studies that have influenced major clinical guidelines:
Aspirin & COX-2 Inhibitors: Supported by the 2025 ALASCCA trial, showing that low-dose aspirin improves outcomes in PIK3CA-mutant colorectal cancer (CRC), leading to updated NCCN guidelines. Broad observational meta-analyses also link daily low-dose aspirin to a 21% reduction in overall cancer mortality.
Exercise: Moderate aerobic activity (≥150 min/week) and resistance training demonstrate a 20–40% reduction in cancer-specific mortality across breast, colorectal, and prostate cancers.
Metformin: Activates AMPK and suppresses systemic insulin/IGF-1 signaling, with population meta-analyses showing 25–40% reduced cancer mortality in diabetic patients.
Statins (e.g., Pitavastatin): Disrupt the mevalonate pathway and Ras/Rho prenylation, associated with 15–35% reductions in cancer-specific mortality.
Cimetidine (H2 Blocker): A Cochrane meta-analysis confirmed a significant overall survival benefit in colorectal cancer (10-year survival 84.6% vs. 49.8% in controls) by blocking E-selectin-mediated tumor cell adhesion.
Tier 2: Moderate Clinical Evidence
Supported by individual RCTs, systematic reviews, or approved indications in narrow cancer types:
BCG Immunotherapy: FDA-approved intravesical gold standard for non-muscle-invasive bladder cancer.
Low-Dose Naltrexone (LDN): Taken at night (1.5–4.5 mg), LDN transiently blocks opioid growth factor receptors (OGFr) to trigger a morning compensatory upregulation of endogenous opioids (OGF), activating p21/p16 cyclin-dependent kinase inhibitors to induce cell cycle arrest.
Perioperative Propranolol: Blunts stress-hormone surges during surgery; the COMPIT trial showed a reduction in perioperative CRC recurrence from 50% to 12.5%.
High-Dose Intravenous Vitamin C: Pharmacologic IV dosing (1.5 g/kg) generates pro-oxidant hydrogen peroxide selectively toxic to tumor cells.
Tumor Treating Fields (TTFields): FDA-approved wearable device generating alternating electric fields that disrupt mitotic spindle formation, proven in Phase III glioblastoma trials.
Repurposed Antiparasitics: Ivermectin (active Phase I/II trial in triple-negative breast cancer) and Benzimidazoles (mebendazole/fenbendazole, backed by Phase II RCT data in CRC).
Tier 3: Emerging Evidence
Backed by strong preclinical mechanisms and observational series, but lacking large RCT confirmation:
Disulfiram + Copper: Inhibits proteasomes and ALDH to target cancer stem cells.
Itraconazole: Antifungal that suppresses Hedgehog signaling, VEGFR2 angiogenesis, and P-glycoprotein resistance.
Berberine & Nanocurcumin: Target AMPK, NF-\(\kappa\)B, and STAT3 pathways to reduce inflammation and metabolic cell proliferation.
PDE5 Inhibitors (Sildenafil/Tadalafil): Suppress myeloid-derived suppressor cells (MDSCs) to enhance T-cell immune surveillance.
Metabolic & Glucose Management: Ketogenic diets, carbohydrate restriction, and GLP-1 receptor agonists target Warburg-effect dependencies and reduce circulating insulin.
Methylene Blue: Enhances mitochondrial Complex IV electron transfer and acts as a photosensitizer in photodynamic therapy.
Tier 4: Experimental / Preclinical
Interventions with plausible biological rationale but limited or no human clinical trial data:
Includes DMSO (chemo potentiator in vitro), Ashwagandha, Hyperbaric Oxygen Therapy (HBOT), Gerson Therapy (unproven historical protocol), Hydralazine, and baseline lifestyle factors (Stress Reduction, Sleep, Sunshine).
2. Anticancer Nutrition & Dietary Foundations
The sources emphasize that pharmacological interventions operate within a metabolic environment dictated by nutrition:
Ultra-Processed Foods & Sugar: Umbrella reviews link ultra-processed foods directly to reduced survival after cancer and 32 adverse health outcomes. Elevated insulin resistance increases cancer risk by 25% across 12 tumor types.
Plant-Based & Mediterranean Diets: High intake of cruciferous vegetables (≥40g/day) reduces colon cancer risk by 17%, while high dietary fiber (25–29g/day) lowers gastric, ovarian, and breast cancer risks by binding circulating estrogens and reducing inflammation.
Meat Preparation & Preservatives: Nitrates and nitrites in processed meats form carcinogenic N-nitroso compounds, while high-heat charring generates mutagenic HCAs and PAHs. Pairing red meat with fiber-rich vegetables (”ristoceutics”) attenuates these risks.
Coffee: Meta-analyses show 3–4 cups of daily coffee is inversely associated with liver, endometrial, and colorectal cancers.
3. High-Dose Antiparasitic Combination Protocols
Off-label combination protocols—such as those popularized by Dr. William Makis—utilize high-dose ivermectin (1.0–2.0 mg/kg/day) paired with mebendazole (1,000–1,500 mg/day) and/or fenbendazole (444–1,000 mg/day).
Pharmacological Rationale: Ivermectin blocks P-glycoprotein efflux pumps, Wnt/\(\beta\)-catenin stem cell renewal, and NF-\(\kappa\)B signaling, while benzimidazoles destabilize tubulin polymerisation and glucose transport.
Observational Data: The 2026 Hulscher et al. prospective cohort (n=197) reported an 84.4% Clinical Benefit Rate and 32.8% No Evidence of Disease (NED) on combined ivermectin + mebendazole.
Safety & Regulatory Cautions: Because these protocols lack randomized control arms, major bodies like ASCO advise against using off-label antiparasitics outside clinical trials due to risks of hepatotoxicity, CYP2C9/CYP3A4 interactions, and unproven population efficacy.
Sources:
OneDayMD Editorial Team. (2026, September 21). Dr. William Makis’s recommended ivermectin, fenbendazole and mebendazole dosages for cancer (2026). Cancer Advisor. https://cancer.aestheticsadvisor.com/2025/10/dr-william-makiss-recommended.html
OneDayMD Editorial Team. (2026, October 2). 30 best alternative and repurposed cancer treatments: Evidence based literature review (2026 update) (F. Yap, Med. Rev.; v2.1). Cancer Advisor. https://cancer.aestheticsadvisor.com/2025/04/best-alternative-cancer-treatments-2025.html